Citable company snapshot
Alnylam Pharmaceuticals's latest SEC-sourced 2026-03-31 period shows $1.17B in revenue and $205.99M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 31, 2026 | $1.17B | $1.10B | +6.4% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $268.64M | $131.72M | +103.9% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $205.99M | $147.19M | +39.9% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $70.50M | $163.56M | -56.9% |
| Free Cash Flow (computed) | Mar 31, 2026 | $48.67M | $140.26M | -65.3% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed Apr 30, 2026; accession 0001628280-26-028605.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
